Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Thursday, 16 May 2019, 07:37 HKT/SGT
Share:
    

Source: Eisai
Eisai to Present Data on Oncology Pipeline and Products at 55th Asco Annual Meeting

TOKYO, May 16, 2019 - (JCN Newswire) - Eisai Co., Ltd. announced today that presentations on a series of abstracts highlighting updates regarding its in-house discovered lenvatinib mesylate (product name: Lenvima, "lenvatinib", kinase inhibitor), eribulin mesylate (product name: Halaven, "eribulin", halichondrin class microtubule dynamics inhibitor), and MORAb-202 (antibody drug conjugate, ADC) will be given at the 55th Annual Meeting of the American Society of Clinical Oncology (ASCO), taking place in Chicago, the United States, from May 31 to June 4, 2019.

The latest information on H3B-6527 (fibroblast growth factor receptor 4 inhibitor) and H3B-6545 (selective estrogen receptor covalent antagonist), which were discovered by Eisai's U.S. oncology precision medicine-focused research and development subsidiary H3 Biomedicine Inc., will also be highlighted in presentations at ASCO.

Major poster presentations at this year's meeting include highlights of the latest data from an ongoing Phase I clinical study investigating Eisai's first ADC MORAb-202 in patients with solid tumors in Japan. MORAb-202 is a novel ADC that combines Eisai's investigational anti-folate receptor (FRA) antibody farletuzumab with Eisai's in-house discovered anticancer agent eribulin as the payload.

Eisai positions oncology as a key therapeutic area, and is aiming to discover revolutionary new medicines with the potential to cure cancer. The company will continue to create innovation in the development of new drugs based on cutting-edge cancer research, as it seeks to contribute further to addressing the diverse needs of, and increasing the benefits provided to, patients with cancer, their families, and healthcare providers.

About the Eisai and Merck & Co., Inc., Kenilworth, N.J., U.S.A. Strategic Collaboration

In March 2018, Eisai and Merck & Co., Inc., Kenilworth, N.J., U.S.A., known as MSD outside the United States and Canada, through an affiliate, entered into a strategic collaboration for the worldwide co-development and co- commercialization of LENVIMA (lenvatinib). Under the agreement, the companies will jointly develop, manufacture and commercialize LENVIMA, both as monotherapy and in combination with Merck & Co., Inc., Kenilworth, N.J., U.S.A.'s anti-PD-1 therapy KEYTRUDA (pembrolizumab).

In addition to ongoing clinical studies evaluating the LENVIMA and KEYTRUDA combination across several different tumor types, including renal cell carcinoma, the companies will jointly initiate new clinical studies through the LEAP (LEnvatinib And Pembrolizumab) clinical program, which will evaluate the combination to support 11 potential indications in six types of cancer (endometrial cancer, hepatocellular carcinoma, melanoma, non-small cell lung cancer, squamous cell carcinoma of the head and neck, and urothelial cancer). The LEAP clinical program also includes a new basket trial targeting six additional cancer types (biliary tract cancer, breast cancer, colorectal cancer, gastric cancer, glioblastoma and ovarian cancer). The LENVIMA and KEYTRUDA combination is not approved in any cancer types today.


About Eisai

Eisai Co., Ltd. is a leading global research and development-based pharmaceutical company headquartered in Japan. We define our corporate mission as "giving first thought to patients and their families and to increasing the benefits health care provides," which we call our human health care (hhc) philosophy. With approximately 10,000 employees working across our global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to realize our hhc philosophy by delivering innovative products in various therapeutic areas with high unmet medical needs, including Neurology and Oncology.

In its medium-term business plan EWAY2025, Eisai is aiming to become a "Medico Societal Innovator" (a company that changes society through creating medicines and providing solutions), and is working on establishment of ecosystem platform business utilizing various data such as a large amount of clinical data, experiences, and know-how.

For more information about Eisai Co., Ltd., please visit https://www.eisai.co.jp.

Contact:
Public Relations Department
Eisai Co., Ltd. 
+81-(0)3-3817-5120


May 16, 2019 07:37 HKT/SGT
Source: Eisai

Eisai (TSE: 4523)

Topic: Press release summary
Sectors: BioTech
http://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2019 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.



Eisai
Nov 20, 2019 13:01 HKT/SGT
Eisai's Equfina 50mg Tablets (Safinamide Mesilate) Launched in Japan
Nov 5, 2019 09:02 HKT/SGT
Eisai Transfers Rights to Receive Royalties Outside of Japan for EZH2 Inhibitor Tazemetostat to Royalty Pharma
Oct 23, 2019 10:13 HKT/SGT
Biogen Plans Regulatory Filing for Aducanumab in Alzheimer's Disease Based on New Analysis of Larger Dataset from Phase 3 Studies
Oct 15, 2019 20:24 HKT/SGT
Eisai's New Drug Approval for Fycompa for Adjunctive Treatment of Partial Onset Seizures in China
Oct 1, 2019 10:46 HKT/SGT
Eisai: Final Study Results Evaluating LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Combination Treatment in Advanced Endometrial Cancer Presented at ESMO 2019 Congress
Sept 30, 2019 11:06 HKT/SGT
Eisai and Nichi-Iko Enter into Collaboration Agreement for Generic Pharmaceutical Business in China
Sept 26, 2019 13:21 HKT/SGT
Eisai and Tokio Marine Nichido Enter Into Business Alliance for Co-Existence and Prevention of Dementia
Sept 26, 2019 13:08 HKT/SGT
Eisai and Fronteo to Launch Coroban Tumbling and Falling Prediction System for Inpatients
Sept 24, 2019 09:01 HKT/SGT
Eisai to Present Abstracts on Oncology Products and Pipeline at ESMO 2019 Congress
Sept 20, 2019 15:13 HKT/SGT
Eisai and Meiji Announce Parkinson's Disease Treatment Equfina Tablets (Safinamide Mesilate) Approved In Japan
More news >>
 News Alerts
Copyright © 2019 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 800 291 0906 | Beijing: +86 400 879 3881 | Hong Kong: +852 2217 2912 | Singapore: +65 6304 8926 | Tokyo: +81 3 6859 8575

Connect With us: